Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons
- PMID: 25933476
- DOI: 10.1016/j.ejvs.2015.02.022
Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons
Comment in
-
Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.Eur J Vasc Endovasc Surg. 2015 Jul;50(1):127. doi: 10.1016/j.ejvs.2015.03.001. Epub 2015 Apr 13. Eur J Vasc Endovasc Surg. 2015. PMID: 25882231 No abstract available.
Comment on
-
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.Eur J Vasc Endovasc Surg. 2014 Nov;48(5):565-75. doi: 10.1016/j.ejvs.2014.05.001. Epub 2014 Jun 18. Eur J Vasc Endovasc Surg. 2014. PMID: 24951377
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
